# CBD side effects: known risks and unanswered questions

https://cbd.bike/guides/cbd-side-effects/

Author: Cryptobedrock (Organization)
Sources checked: 2026-10-19

> CBD can cause drowsiness, digestive symptoms, liver problems and medicine interactions. Risk depends on the formulation, exposure and individual circumstances.

## Known concerns

Public health guidance identifies possible drowsiness, digestive symptoms, appetite changes, and drug interactions. There are also concerns about liver injury. People may not recognize every adverse effect without clinical monitoring. [1]

## What a liver study tells us

An FDA-described randomized trial studied repeated oral CBD use in healthy adults. Some participants developed liver enzyme elevations. That result supports taking liver safety seriously; it does not establish the risk of every retail product or define a universally safe amount. [2]

## Situations that deserve extra care

Pregnancy and breastfeeding are reasons to avoid CBD under FDA guidance. Children should not be given consumer CBD products as an experiment; a prescribed CBD medicine is a different, medically supervised situation. [3]

## A useful next step

Before use, ask a clinician or pharmacist about your medications, liver history, and the full product formula. If symptoms appear, stop using the product and seek medical advice. Severe symptoms need urgent care. Keep the packaging so a professional can identify what you took.

## Read a safety finding at the right level

A symptom diary, a blood test and a clinical diagnosis answer different questions. Keeping them separate makes safety information easier to use.

| Observation | What it tells you | What it does not settle |
| --- | --- | --- |
| A person reports no symptoms | No symptoms were noticed or reported. | Whether a laboratory value changed. |
| A liver enzyme exceeds a study threshold | The predefined laboratory endpoint occurred. | A diagnosis for everyone using a retail product. |
| Healthy adults in a short trial | Evidence about that population and study period. | Pregnancy, existing liver disease or long-term use. |
| A product has a clean contaminant report | The listed contaminants met the reported criteria. | The effects of CBD itself or a medicine combination. |

The [FDA-described randomized trial](https://www.fda.gov/drugs/regulatory-science-action/cder-investigators-address-safety-cbd-randomized-trial) enrolled 201 healthy adults. Liver-enzyme elevations occurred during its 28-day CBD study, although participants did not report related clinical symptoms. That distinction matters: a symptom-free experience cannot independently rule out the laboratory finding.

Imagine a product review stating that nobody felt unwell. Before treating that as a safety result, ask whether anyone actually measured the endpoint being discussed. An unmeasured outcome is missing information, not a normal test. Equally, a laboratory threshold should not be rewritten as a diagnosis of severe disease in every participant. Record the population, duration and endpoint beside the conclusion. The [FDA pregnancy guidance](https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding) addresses another population and advises against CBD use during pregnancy and breastfeeding. It cannot be replaced by findings in healthy, nonpregnant adults. These are separate evidence questions, even when the same ingredient appears in both.

1. **Name the observation:** Symptom, laboratory result or diagnosis?
2. **Check who was studied:** Population and duration limit the conclusion.
3. **Record the unresolved part:** An unmeasured outcome remains unknown.

Bring a dated product list, relevant medical history and any symptom timeline to the clinician assessing your situation.

Scope: A short monitored study does not determine the risk of every formulation, person or duration of use.

## Does no noticeable side effect mean no laboratory change?

No. Reported symptoms and measured laboratory outcomes are different observations.

## Does a contaminant pass establish that CBD itself is risk-free?

No. A contaminant panel does not assess all effects of an ingredient, a medication combination or an individual medical history.

## Sources

1. [CDC · About CBD](https://www.cdc.gov/cannabis/about/about-cbd.html)
2. [FDA · Randomized CBD liver safety trial](https://www.fda.gov/drugs/regulatory-science-action/cder-investigators-address-safety-cbd-randomized-trial)
3. [FDA · Cannabis, CBD, pregnancy and breastfeeding](https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding)
4. [FDA · Randomized CBD liver-safety trial](https://www.fda.gov/drugs/regulatory-science-action/cder-investigators-address-safety-cbd-randomized-trial)
5. [FDA · CBD, pregnancy and breastfeeding](https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding)

Educational text without clinical or veterinary peer review. Not a personal treatment plan.

## A laboratory signal can appear without noticeable symptoms

In the 28-day FDA trial, eight CBD recipients crossed the ALT/AST threshold. The reported Kaplan–Meier estimate was 5.6% (95% CI 1.8–9.3%), compared with 0% (0–7.6%) for placebo. Numbers at risk at week four were 141 and 47.

| Group | Estimate and 95% CI | Events / number at risk at week 4 |
| --- | --- | --- |
| CBD solution | 5.6% (1.8–9.3%) | 8 / 141 |
| Placebo | 0% (0–7.6%) | 0 / 47 |

The study randomized 201 healthy adults and studied an oral CBD solution at 250–550 mg/day. This is the study exposure, not a use recommendation. The result is a liver-enzyme endpoint, not the rate of symptomatic liver failure or a prediction for every retail product.

[FDA · Randomized CBD liver-safety trial](https://www.fda.gov/drugs/regulatory-science-action/cder-investigators-address-safety-cbd-randomized-trial)